Perspective Therapeutics (CATX) Financial Statements & Analysis

Perspective Therapeutics (CATX) Income Statement

Perspective Therapeutics reported revenue of $884.00K in fiscal 2025 (fiscal year ended Dec 31, 2025), down 39.2% from $1.45M a year earlier. Perspective Therapeutics posted a net loss of $103.12M, compared with a net loss of $79.28M a year earlier. Gross margin was 100.0% and operating margin -12846.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $81.00K, down 72.1% from the same quarter a year earlier.

Perspective Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Perspective Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018
Revenue & Gross Profit
Revenue	0.88	1.45	1.43	5.42	10.05	10.05	9.68	7.31
Cost of Revenue	84.22	2.31	0.00	3.05	4.93	4.93	4.56	4.27
Gross Profit	0.88	-0.85	1.43	4.62	5.12	5.12	5.12	3.05
Operating Expenses
Research & Development	84.22	39.33	21.31	0.85	1.43	1.43	1.13	1.47
Selling, General & Administrative	30.23	26.61	21.06	5.57	7.13	7.13	7.55	6.85
Operating Expenses	114.45	65.94	42.38	6.42	8.56	8.56	8.60	8.33
Operating Income	-113.56	-66.80	-40.94	-6.42	-3.44	-3.44	-3.48	-5.28
Other Income/Expense
Interest Income	8.11	10.52	0.93	0.62	0.06	0.06	0.03	0.11
Interest Expense	0.38	0.05	0.08	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	9.65	-13.63	0.84	-0.85	-0.01	0.05	0.03	0.13
Income
Income Before Tax	-104.43	-80.43	-40.11	-6.30	-3.39	-3.39	-3.45	-5.14
Income Tax Expense	-0.79	-2.10	-2.65	0.00	0.00	-0.20	-0.18	-0.29
Net Income	-103.12	-79.28	-46.51	-7.27	-3.39	-3.19	-3.27	-4.85
Net Income - Continuous Operations	-103.12	-79.28	-46.51	-10.76	-3.39	-3.19	-3.27	-4.85
Net Income - Discontinued Operations	0.51	-0.95	-9.05	-	-	-	-	-
EBITDA	-110.32	-64.49	-39.96	-6.14	-3.29	-3.43	-3.48	-5.14
EBIT	-113.56	-66.80	-40.94	-6.42	-3.44	-	-	-
Depreciation & Amortization	3.25	2.31	0.98	0.28	0.15	0.01	0.15	0.14
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-1.00	-	-	-	-
Diluted EPS	-1.00	-1.00	-1.00	-	-	-	-	-
Basic Shares Outstanding	73.81	64.43	54.91	14.20	10.38	54.91	67.60	67.04
Diluted Shares Outstanding	73.81	64.43	54.91	14.20	10.38	54.91	67.60	67.04

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Perspective Therapeutics Financial Statements

What was Perspective Therapeutics's revenue in fiscal 2025?

Perspective Therapeutics reported revenue of $884.00K in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 39.2% from $1.45M a year earlier.

Is Perspective Therapeutics profitable?

No. Perspective Therapeutics reported a net loss of $103.12M in fiscal 2025. In fiscal 2024 it lost $79.28M.

What is Perspective Therapeutics's operating margin?

Perspective Therapeutics's operating income was −$113.56M on revenue of $884.00K in fiscal 2025, an operating margin of -12846.6%, compared with -4594.0% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition